Compact Proton Therapy System by Hitachi at Shonan Kamakura Advanced Medical Center

Compact Proton Therapy System-Hitachi, Ltd. (TSE: 6501) has announced that “Shonan Kamakura Advanced Medical Center” at Shonan Kamakura General Hospital of Tokushukai Medical Group, where Hitachi’s compact proton therapy system (hereafter, “the system”) has been installed, has commenced treatment with the system on 31 January 2022. This is the first order for Hitachi’s dedicated compact proton therapy system.

Shonan Kamakura Advanced Medical Center is a medical facility providing comprehensive cancer treatment, including advanced radiotherapy, built adjacent to the site of Shonan Kamakura General Hospital by Tokushukai Group Medical Corporation, which operates approximately 400 medical facilities and nursing homes throughout Japan.

Until now, there have been no proton therapy facilities in Kanagawa Prefecture, where the center is located, but the compact proton therapy system, with its reduced footprint, makes it possible to install a proton therapy facility on a limited site close to the city center.

Features of the installed system

In response to the growing worldwide demand for smaller proton therapy systems, Hitachi has developed the proton therapy system, which is specifically designed for a single treatment room. The system is a compact proton therapy system which, by optimizing the layout of the machine, reduces the installation area to about 70% of that of conventional solutions, making it possible to install the system on a limited site in an urban area and reducing the cost and time involved in its installation.

It is equipped with advanced technologies such as spot scanning irradiation technology, which allows the proton beam to be delivered according to the shape of the cancer, a 360degree rotating gantry with cone-beam CT(1) for high-precision positioning, and Real-time image Gated Proton Therapy (RGPT)(2), making it both compact and highly functional.

Hitachi is committed to accelerating the global development of particle therapy system and contributing to cancer treatment around the world, as well as to further expanding its healthcare services.

(1) Cone beam CT provides three-dimensional anatomical images of patients, at isocenter immediately prior to being treated. Information on the location of bone is obtained from traditional orthogonal x-rays and the motion of tumors is captured by RGPT. These are then combined with the ability to identify healthy tissue surrounding a tumor, particularly the location and shape of soft tissue, via Cone beam CT.

(2) RGPT allows real-time beam irradiation to the tumor while compensating for movement associated with respiration. This technology was collaboratively developed between Hokkaido University and Hitachi, and supported by the Funding Program for World-Leading Innovative R&D on Science and Technology (FIRST) of the Japan Society for the Promotion of Science.

Overview of Particle Therapy

Particle Therapy is an advanced type of cancer radiotherapy. Protons extracted from hydrogen atoms, or carbon ions are accelerated up to 70% of the speed of light. This energy is concentrated directly on the tumor while minimizing radiation dose to surrounding healthy tissue. Particle therapy improves the quality of life for cancer patients since the patient experiences no pain during treatment and the procedure has very few side effects compared to that of traditional radiotherapy. In most cases, patients can continue with their normal daily activities while undergoing treatment.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”